Related Experiment Video
Updated: May 31, 2026
11:07
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
Nanoparticulate Immunoactive Complex for Local Chemoimmunotherapy: From Murine Models to Pilot Canine Study
Yanying He1, Jiaqi Zhao1, Jung Suk Kim1
1Department of Industrial and Molecular Pharmaceutics, Purdue University, West Lafayette, Indiana.
Cancer Research Communications
|May 29, 2026
Summary
Local delivery of immunoactive complex (IMAX) nanoparticles demonstrated safety and efficacy in preclinical models. IMAX remained localized, activated immune responses, and achieved tumor regression in mice and dogs with cancer.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Chemoimmunotherapy harnesses the immune system for tumor control and lasting antitumor immunity.
- A previously developed nanoparticulate immunoactive complex (IMAX) showed significant antitumor activity in mouse models after intratumoral administration.
Purpose of the Study:
- Evaluate the biodistribution and determine a safe, effective dose of locally delivered IMAX in mice.
- Inform pilot safety and efficacy studies of IMAX in dogs with naturally occurring cancer.
Main Methods:
- Intratumoral administration of IMAX in mouse models.
- Biodistribution analysis and dose-ranging studies in mice.
- Safety and tolerability assessment in laboratory dogs.
- Pilot efficacy study in companion dogs with naturally occurring cancer, including histological and transcriptomic analyses.
Main Results:
- In mice, IMAX showed localized retention, minimal systemic exposure, and induced immune cell infiltration, leading to complete tumor regression at reduced doses.
- Laboratory dogs tolerated IMAX well, with transient, manageable adverse events.
- In dogs with cancer, IMAX induced immune cell infiltration, necrosis, and early innate immune pathway activation, resulting in antitumor effects, particularly in mammary carcinoma.
Conclusions:
- Local IMAX therapy is feasible and safe in tumor-bearing dogs.
- Further investigation with optimized dosing and combination strategies is warranted for canine cancer treatment.
